Staurosporine-induced apoptosis of HPV positive and negative human cervical cancer cells from different points in the cell cycle

Cell Death Differ. 2001 Mar;8(3):234-44. doi: 10.1038/sj.cdd.4400796.

Abstract

In the present study, we compare the sensitivity of CaSki and HeLa cells (HPV positive, wild-type p53) and C33A cells (HPV negative, mutated p53) to a protein kinase inhibitor, the staurosporine (ST). We show that ST can reversibly arrest the three cervical-derived cell lines, either in G1 or in G2/M. Beyond certain ST concentrations or/and over 24 h exposure, the cells underwent apoptosis. This process took place in G1 and G2/M for C33A and CaSki plus HeLa cell lines, respectively. By using an in vitro cell-free system, we demonstrated that cytoplasmic extracts from apoptotic cells were sufficient to induce hallmarks of programmed cell death on isolated nuclei. Moreover, we found that only G2/M cytoplasmic extracts from viable CaSki and HeLa cells supplemented with ST, triggered apoptosis while exclusively G1 cytoplasmic fractions from C33A cells were efficient. Our study describes a possible involvement of the HPV infection or/and p53 status in this different ST-induced apoptosis susceptibility.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Apoptosis / physiology
  • Cell Cycle / drug effects
  • Cell Cycle / genetics
  • Cell Cycle / physiology*
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Cell Nucleus / drug effects
  • Cell Nucleus / physiology
  • Drug Administration Schedule
  • Female
  • Flow Cytometry
  • G1 Phase / drug effects
  • G2 Phase / drug effects
  • HeLa Cells
  • Human papillomavirus 18*
  • Humans
  • In Situ Nick-End Labeling
  • Papillomavirus Infections / pathology*
  • Staurosporine / pharmacology*
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / pathology*
  • Uterine Cervical Neoplasms / virology

Substances

  • Staurosporine